ConductScience.org, home

Paper8595151

Aromatase inhibitors--where are we now?

Miller WR. Br J Cancer, 1996. Cited by 37 papers, by iCite.

Cite this record

ConductScience Library. Aromatase inhibitors--where are we now? Papers, record 8595151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8595151

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Aromatase inhibitors--where are we now?
PubMed
Journal
Br J Cancer
PubMed
Year
1996
PubMed
Publication types
Editorial
PubMed
Citations, by iCite
37
iCite
Relative citation ratio, by iCite
1.22
iCite
Revised in PubMed
2019-05-15
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Miller WRW R

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, HormonalMajor topic
Aromatase InhibitorsMajor topic
Breast NeoplasmsMajor topic
Enzyme InhibitorsMajor topic
NeoplasmsMajor topic
Female
Humans

Source PubMed

Download CSV of topics

References16

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
14811847Diabetes mellitus associated with epidemic of infectious hepatitis in Nigeria.Br Med J1974https://conductscience.org/library/papers/4811847PubMed
27873457Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.Ann Oncol1994https://conductscience.org/library/papers/7873457PubMed
36213633Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.J Clin Endocrinol Metab1982https://conductscience.org/library/papers/6213633PubMed
42527597Aromatase inhibitors in the treatment of advanced breast cancer.Cancer Treat Rev1989https://conductscience.org/library/papers/2527597PubMed
52369789Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.Cancer Chemother Pharmacol1990https://conductscience.org/library/papers/2369789PubMed
62278830Endocrine treatment for breast cancers: biological rationale and current progress.J Steroid Biochem Mol Biol1990https://conductscience.org/library/papers/2278830PubMed
78386541The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer.J Steroid Biochem Mol Biol1993https://conductscience.org/library/papers/8386541PubMed
88240982Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3 beta,17 beta-diol in human mammary cancer cells.J Steroid Biochem Mol Biol1993https://conductscience.org/library/papers/8240982PubMed
97949208Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.Breast Cancer Res Treat1994https://conductscience.org/library/papers/7949208PubMed
107954417Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.Cancer Res1994https://conductscience.org/library/papers/7954417PubMed
117955367Recent advances in biochemical markers of bone turnover.Clin Chem1994https://conductscience.org/library/papers/7955367PubMed
127833101Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer.Eur J Cancer1994https://conductscience.org/library/papers/7833101PubMed
137697604Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer.Cancer1995https://conductscience.org/library/papers/7697604PubMed
147749129Aromatase inhibitor development for treatment of breast cancer.Breast Cancer Res Treat1995https://conductscience.org/library/papers/7749129PubMed
159815984Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.Clin Cancer Res1995https://conductscience.org/library/papers/9815984PubMed
166797571Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.Br Med J (Clin Res Ed)1981https://conductscience.org/library/papers/6797571PubMed

Download CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.

PMIDTitleJournalYearIn PapersSource
26294292Elevated incidence of fractures in women with invasive breast cancer.Osteoporos Int2016https://conductscience.org/library/papers/26294292PubMed
25429284Estrogen biosynthesis and action in ovarian cancer.Front Endocrinol (Lausanne)2014https://conductscience.org/library/papers/25429284PubMed
10917548Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide.Br J Cancer2000https://conductscience.org/library/papers/10917548PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8595151

GET https://conductscience.org/api/papers/v1/8595151/authors